Here we report, for the first time to our knowledge, the identification of heterozygous SOX2 mutations in two unrelated patients in association with pituitary tumors of likely congenital origin and we provide in vitro evidence that disruption of the SOX2/β-catenin interaction may be the molecular mechanism underlying some human pituitary tumors. This evidence concerns the gene SOX2 and pituitary tumor.